Heredia, A., Latinovic, O., Gallo, R. C., Melikyan, G., Reitz, M., Le, N., & Redfield, R. R. (2008). Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. National Academy of Sciences.
Čikaški stil citiranjaHeredia, Alonso, Olga Latinovic, Robert C. Gallo, Gregory Melikyan, Marv Reitz, Nhut Le, i Robert R. Redfield. Reduction of CCR5 With Low-dose Rapamycin Enhances the Antiviral Activity of Vicriviroc against Both Sensitive and Drug-resistant HIV-1. National Academy of Sciences, 2008.
MLA način citiranjaHeredia, Alonso, et al. Reduction of CCR5 With Low-dose Rapamycin Enhances the Antiviral Activity of Vicriviroc against Both Sensitive and Drug-resistant HIV-1. National Academy of Sciences, 2008.